Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?
- Here is how Aerie Pharmaceuticals (AERI) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
- 08/26/2022
|
Why Aerie Pharmaceuticals Was Soaring So High This Week
- You'd vault skyward, too, if a big-pocketed company were willing to spend a lot of coin on acquiring you.
- 08/26/2022
|
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
- Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.
- 08/24/2022
|
Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up
- Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.
- 08/23/2022
|
Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share
- Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.
- 08/23/2022
|
After Golden Cross, Aerie Pharmaceuticals (AERI)'s Technical Outlook is Bright
- Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
- 08/17/2022
|
Aerie Pharmaceuticals, Inc.'s (AERI) CEO Raj Kannan on Q2 2022 Results - Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Hans Vitzthum – Investor Relations Raj Kannan – Chief Executive Officer Peter Lang – Chief Financial Officer Gary Sternberg – Chief Medical Officer Michelle Senchyna – Head-Clinical Development and Operations Casey Kopczynski – Co-Founder, Head-Research and External Innovation Conference Call Participants Serge Belanger – Needham Annabel Samimy – Stifel Stacy Ku – Cowen Greg Fraser – Truist Operator Good afternoon. Thank you for standing by, and welcome to the Aerie Pharmaceuticals Second Quarter 2022 Earnings Conference Call.
- 08/07/2022
|
Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat
- Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.
- 08/05/2022
|
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of 38.46% and 2.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss Aerie's financial results and provide a general business update
- 07/28/2022
|
Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
- Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.
- 05/25/2022
|
Aerie Pharmaceuticals' (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Hans Vitzthum – LifeSci Partners Raj Kannan – Chief Executive Officer Gary Sternberg – Chief Medical Officer Peter Lang – Chief Financial Officer Conference Call Participants Louise Chen – Cantor Serge Belanger – Needham & Company Annabel Samimy – Stifel Stacy Ku – Cowen and Company François Brisebois – Oppenheimer Carly Kenselaar – Citigroup Oren Livnat – H.C. Wainwright Operator Good afternoon.
- 05/07/2022
|
Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
- Aerie (AERI) misses on both earnings and revenues for the first quarter of 2022.
- 05/06/2022
|
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of -1.54% and 1.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Aerie (AERI) Expands Market Presence Despite Stiff Competition
- Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.
- 04/11/2022
|
Aerie Pharmaceuticals (AERI) Stock: Why It Substantially Increased
- The Aerie Pharmaceuticals Inc (NASDAQ: AERI) stock increased by 29.49% in the most recent trading session. This is why.
- 02/27/2022
|
Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More
- Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.
- 02/23/2022
|
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
- DURHAM, N.C.--(BUSINESS WIRE)--AERI 4Q & FY21 Save-the-Date
- 02/17/2022
|
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences. Stifel 2021 Virtual Healthcare Conference Date: T
- 11/09/2021
|
Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript
- Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript
- 11/07/2021
|
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
- Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.
- 11/05/2021
|
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/04/2021
|
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (“netarsudil 0.02%”) versus ripasudil hydrochloride hydrate ophthalmic solution 0.4% (“ripasudil 0.4%”). The results showed that netarsudil 0.02% once daily was superior to ripasudil 0.4% twice daily in lowering intraocular pressure (“IOP”) at week
- 10/12/2021
|
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie's retina product candidates, at the Ophthalmology Innovation Summit Retina Innovation Showcase. The slide presentation addresses Aerie's proprietary PRINT® drug delivery platform and retina product candidates AR-1105 (dexamethasone implant, Phase 3 ready), AR-13503 (Rho kinase/Protei
- 10/07/2021
|
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial in patients with macular edema due to retinal vein occlusion will be presented at the 39th Annual Scientific Meeting of the American Society of Retina Specialists in San Antonio, Texas. The presentation entitled “Phase 2 Study of Two Formulations of AR-1105 in Macular Ede
- 10/06/2021
|
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin F. McGraw, III, Pharm.D., Interim Executive Chairman and David A. Hollander, M.D., M.B.A., Chief R&D Officer, will participate in a fireside discussion at the
- 09/27/2021
|
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicente Anido, PhD. no longer serves as the Company's Chairman and Chief Executive Officer or as a director of the Company. Consistent with the succession plan in place, the Company's Board of Directors has appointed Benjamin F. McGraw, III, Pharm.D. a
- 09/21/2021
|
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment Erik Pacyniak, Ph.D., D.A.B.T., Director, Toxicology, reporting to Jeff White, Ph.D., D.A.B.T., Aerie's Vice President of Research and Discovery. Dr. Pacyniak will ove
- 09/20/2021
|
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results of its Phase 2b clinical study, named COMET-1, for AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye diseas
- 09/15/2021
|
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Carolyn McAuliffe, Senior Director, Communications, reporting to Tad Heitmann, Aerie's Vice President of Marketing. Ms. McAuliffe will be responsible for the develo
- 09/13/2021
|
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will participate in the following virtual investor conferences. Citi 16th Annual BioPharma Conference Date:
- 09/07/2021
|
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Casey C. Kopczynski, Ph.D., Chief Scientific Officer, will participate in a virtual panel discussion titled, “What are the Greatest Unmet Needs Facing Ophthalmology Today?”, at
- 08/12/2021
|
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q2 2021 Results - Earnings Call Transcript
- Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of -3.08% and 2.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases today announced the appointment of Leon J. Atencia, Director of Regulatory Affairs, reporting to Emma Beausang, Aerie's Vice President of Regulatory Affairs. Mr. Atencia will be responsible for clini
- 07/15/2021
|
Aerie Pharmaceuticals to Participate in the Raymond James Human Health Innovation Conference – UPDATED RELEASE
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Raymond James Human Health Innovation Conference on Tuesday, June
- 06/21/2021
|
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for its first Phase 3 clinical trial of netarsudil ophthalmic solution in Japan, comparing netarsudil ophthalmic solution 0.02% (“netarsudil”),
- 06/17/2021
|
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
- Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
- 05/06/2021
|
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript
- 05/06/2021
|
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Misses Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of -4.35% and -1.64%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2021
|
Is a Surprise Coming for Aerie (AERI) This Earnings Season?
- Aerie (AERI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/04/2021
|
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for COMET-1, a Phase 2b clinical trial of AR-15512 (TRPM8 Agonist) (“AR-15512”) ophthalmic solution for the treatment of patients with dry eye d
- 04/29/2021
|
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2021
|
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters wi
- 04/28/2021
|
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great Britain
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) (“Roclanda®”) has received marketing authorisation from the Medicines and Healthca
- 04/19/2021
|
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Ap
- 04/07/2021
|
Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucoma
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the publication of a peer-reviewed paper in eLife, a science journal, entitled, “Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure h
- 03/30/2021
|
Aerie (AERI) Up 11.8% Since Last Earnings Report: Can It Continue?
- Aerie (AERI) reported earnings 30 days ago. What's next for the stock?
- 03/27/2021
|
Aerie (AERI) Rises Despite Q4 Earnings Miss, Revenues Top Mark
- Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.
- 03/01/2021
|
Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q4 2020 Results - Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q4 2020 Results - Earnings Call Transcript
- 02/26/2021
|
Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of -5.33% and 13.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/25/2021
|
Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company will participate in the following virtual investor conferences. 10th Annual SVB Leerink Global Healthcare Conference Date: Friday, February 26, 2021 Time: 2:20 p.m.
- 02/22/2021
|
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its fourth quarter and full year 2020 financial results will be released after the market closes on Thursday, February 25, 2021. Following the release, the Company will host a
- 02/18/2021
|
Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the European Commission (EC) has granted a marketing authorisation for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated intraocu
- 01/11/2021
|
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript
- Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript
- 11/05/2020
|
Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
- OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa® and Rocklatan® in Japan, along with rights for several other Asian countries. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
- 10/28/2020
|
Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
- DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020. Following the release, the Company will host a live conference c
- 10/27/2020
|
Europe Glaucoma Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares 2016-2024 - ResearchAndMarkets.com
|
Next Generation Cancer Diagnostics: Technologies and Global Markets (2019-2025) - ResearchAndMarkets.com
|
New Strong Sell Stocks for August 10th
- Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- 08/10/2020
|
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
- Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
- 08/07/2020
|
Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a general business update.
- 08/06/2020
|
Analysts Anticipate Aerie Pharmaceuticals Inc (NASDAQ:AERI) to Announce -$0.79 Earnings Per Share
- Analysts predict that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will post ($0.79) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.86) and the highest is ($0.67). Aerie Pharmaceuticals reported earnings per share of ($0.80) in the same quarter […]
- 08/05/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Short Interest Update
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 8,050,000 shares, a drop of 10.6% from the June 30th total of 9,000,000 shares. Based on an average daily volume of 879,200 shares, the short-interest ratio is currently 9.2 days. Currently, 18.4% of […]
- 08/04/2020
|
Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its second quarter 2020 financial results will be released after the market closes on Thursday, August 6, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
- 07/30/2020
|
Will Aerie Pharmaceuticals (AERI) Report Negative Q2 Earnings? What You Should Know
- Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/29/2020
|
Celsion Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
- Celsion advances Phase II advanced ovarian cancer trial. Zentalis inks clinical collaboration with Eli Lilly.
- 07/28/2020
|
Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive topline results for the Company’s Phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion.
- 07/27/2020
|
Contrasting Aerie Pharmaceuticals (NASDAQ:AERI) & Seattle Genetics (NASDAQ:SGEN)
- Aerie Pharmaceuticals (NASDAQ:AERI) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Profitability This table compares Aerie Pharmaceuticals and Seattle Genetics’ net margins, return on equity and return […]
- 07/19/2020
|
Did Hedge Funds Make The Right Call On Aerie Pharmaceuticals Inc (AERI) ?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/17/2020
|
Parametric Portfolio Associates LLC Lowers Stock Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Parametric Portfolio Associates LLC reduced its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 64.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,762 shares of the company’s stock after selling 110,657 shares during the period. Parametric Portfolio […]
- 07/05/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Shares Purchased by Geode Capital Management LLC
- Geode Capital Management LLC increased its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 7.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 636,914 shares of the company’s stock after purchasing an additional 44,751 shares during the period. Geode Capital Management […]
- 07/04/2020
|
Legal & General Group Plc Has $285,000 Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Legal & General Group Plc lessened its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 8.5% in the 1st quarter, Holdings Channel reports. The firm owned 21,085 shares of the company’s stock after selling 1,959 shares during the period. Legal & General Group Plc’s holdings in Aerie Pharmaceuticals were worth $285,000 at the end of the […]
- 07/04/2020
|
Victory Capital Management Inc. Has $88,000 Stock Holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Victory Capital Management Inc. lessened its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 22.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,514 shares of the company’s stock after selling 1,856 shares during the period. Victory Capital […]
- 07/04/2020
|
Is Aerie Pharmaceuticals a Buy?
- Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?
- 07/02/2020
|
Aerie Pharma (AERI) Gets a Buy Rating from Needham - Markets
- In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI – Research Report),
- 06/26/2020
|
Assessment of COVID-19's Effect on Ophthalmology Therapeutics Market 2020-2024 | Increase in Prevalence of Eye Diseases to Augment Growth | Technavio
- The Global Ophthalmology Therapeutics Market will grow by USD 10.42 bn during 2020-2024
- 06/22/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Now Covered by Needham & Company LLC
- Analysts at Needham & Company LLC initiated coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a research report issued on Friday, TipRanks reports. The brokerage set a “buy” rating and a $38.00 price target on the stock. Needham & Company LLC’s price target indicates a potential upside of 143.59% from the company’s current price. A […]
- 06/21/2020
|
Alliancebernstein L.P. Purchases 78,385 Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Alliancebernstein L.P. grew its position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 11.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 740,244 shares of the company’s stock after buying an additional 78,385 shares during the quarter. Alliancebernstein L.P.’s holdings […]
- 06/20/2020
|
Needham Maintains a Buy Rating on Aerie Pharma (AERI) - Markets
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),
- 06/19/2020
|
Aerie Pharmaceuticals Inc (AERI): Hedge Funds Are Nibbling
- Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- 06/15/2020
|
Aerie Takes to TikTok to Spread Positivity in Quarantine
- The platform's most followed user, Charli D'Amelio, launches #AerieREAL Positivity challenge.
- 06/12/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row - Markets
- After Mizuho Securities and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy,
- 06/12/2020
|
Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance and Compensation Committees of the Board.
- 06/11/2020
|
Aerie Looks Modestly Undervalued Despite High Cash Burn (NASDAQ:AERI)
- Aerie has 2 marketed products and decent pipeline after a recent acquisition. Aerie unfortunately still has extremely high cash burn for a company of its size.
- 06/06/2020
|
Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue?
- Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 06/05/2020
|
Why American Eagle Outfitters Stock Popped Today | The Motley Fool
- Shares of the teen apparel retailer were up following its first-quarter earnings release.
- 06/03/2020
|
American Eagle's stock falls after loss and revenue disappoint, dividend suspended
- Shares of American Eagle Outfitters Inc. undefined dropped 4.9% in premarket trading Wednesday, after the apparel, accessories and personal care retailer...
- 06/03/2020
|
Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT
- Q1 2020 Aerie Pharmaceuticals Inc Earnings Call
- 06/03/2020
|
Oppenheimer Maintains Outperform on Aerie Pharmaceuticals, Raises Price Target to $24
|
Female Innerwear Market Size, Share 2020 Globally Industry Demand, Trends, Regional Overview, Top Manufacture, Business Growth and Forecast to 2026, Says Industry Research Biz
- May 24, 2020 (The Expresswire) --
Global “Female Innerwear Market” is a comprehensive research that provides information regarding Female Innerwear market...
- 05/24/2020
|
Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.
|
Was The Smart Money Right About Aerie Pharmaceuticals Inc (AERI)?
- Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
- 05/11/2020
|
Shares of several healthcare companies are trading higher after US unemployment figures came in below consensus estimates. Equities have been strong this week amid a rebound in oil prices and some US states easing lockdown restrictions.
|
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
- Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Computer Programs and Systems Inc : Cantor Fitzgerald raises to overweight from neutral
* Epam Systems Inc : Citigroup raises price target to $265 from $245
* PayPal Holdings Inc : Citigroup raises price target to $145 from $131
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical
order.
* Aaron's Inc : Keybanc cuts target price to $55 from $66
* Aaron's Inc : Raymond James cuts target price to $50 from $60
* Aaron's Inc : Stephens raises target price to $45 from $26
* Abeona Therapeutics Inc : RBC cuts target price to $7 from $11
* Acceleron pharma Inc : Credit Suisse raises target price to $123 from $99
* ACI Worldwide Inc : Canaccord Genuity cuts target price to $35 from $44
* Acushnet Holdings Corp : Jefferies raises target price to $25 from $24
* Acushnet Holdings Corp : JP Morgan raises target price to $30 from $27
* Adtran Inc : Cowen and Company raises price target to $13 from $9
* Aeglea Bio Therapeutics Inc : Needham cuts price target to $11 from $14
* Aerie Pharmaceuticals Inc : Citigroup cuts price target to $38 from $39
* Agco Corp : Citigroup cuts price target to $55 from $57
* AIG : KBW raises target price to $36 from $35
* Alaska Air Group Inc : Credit Suisse cuts target price to $51 from $82
* Allison Transmission Holdings Inc : Citigroup raises price target to $39 from $38
* Allscripts Healthcare Solutions : Cantor Fitzgerald cuts PT to $6 from $8
* Alteryx Inc : Guggenheim cuts target price to $130 from $160
* American Airlines : Credit Suisse cuts target price to $4 from $26
* Ameriprise Financial Inc : Credit Suisse raises target price to $165 from $153
* Ameriprise Financial Inc : Piper Sandler raises target price to $150 from $130
* Amerisourcebergen Corp : Baird raises target price to $115 from $109
* Amerisourcebergen Corp : Mizuho raises target price to $90 from $85
* Amtech Systems Inc : Cowen and Company raises target price to $7.50 from $7
* Angi Homeservices Inc : Needham raises target price to $11 from $8
* Ani Pharmaceuticals Inc : Guggenheim cuts target price to $48 from $58
* Ansys Inc : RBC raises target price to $260 from $230
* Anthem Inc : Bernstein raises target price to $357 from $342
* Appian Corp : Cowen and Company raises price target to $44 from $39
* Applied Optoelectronics Inc : D.A. Davidson raises target price to $12 from $10
* Applied Optoelectronics Inc : Piper Sandler raises target price to $10 from $7.50
* Aptiv Plc : Citigroup raises price target to $84 from $67
* ArcelorMittal SA : Keybanc raises target price to $15 from $13
* Arcturus Therapeutics Holdings Inc : Baird raises target price to $44 from $26
* Arcturus Therapeutics Holdings Inc : Guggenheim raises target price to $51 from $41
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Athersys Inc : Needham cuts price target to $5 from $6
* Atlas Air Worldwide Holdings Inc : Cowen and Company raises PT to $44 from $40
* Avalara Inc : Canaccord Genuity raises target price to $115 from $105
* Avalara Inc : JP Morgan raises target price to $120 from $104
* Avalara Inc : Mizuho raises price target to $120 from $85
* Avalara Inc : Piper Sandler raises target price to $113 from $90
* Avalonbay Communities Inc : Stifel raises target price to $176 from $171
* Avrobio Inc : Guggenheim raises target price to $50 from $49
* Axalta Coating Systems Ltd : RBC raises target price to $21 from $20
* Bausch Health Companies Inc : Piper Sandler cuts target price to $32 from $34
* Beacon Roofing Supply Inc : SunTrust Robinson raises target price to $26 from $24
* Beacon Roofing Supply Inc : Wedbush raises target price to $23 from $16
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Becton Dickinson and Co : Evercore ISI raises target price to $270 from $255
* Beyond Meat Inc : Berenberg raises price target to $125 from $115
* Bill.Com Holdings Inc : Canaccord Genuity raises target price to $65 from $50
* Bill.Com Holdings Inc : Jefferies raises target price to $70 from $45
* Bill.Com Holdings Inc : Keybanc raises target price to $76 from $60
* Bill.Com Holdings Inc : Needham raises target price to $90 from $55
* Biomarin Pharmaceutical Inc : Canaccord Genuity raises PT to $119 from $108
* BJ's Restaurants Inc : Wedbush cuts target price to $32 from $39
* Booking Holdings Inc : Credit Suisse raises target price to $1,810 from $1,790
* Booking Holdings Inc : Jefferies cuts target price to $1300 from $1350
* Booking Holdings Inc : Mizuho cuts price target to $1700 from $1720
* Booking Holdings Inc : RBC raises target price to $1,550 from $1,535
* Booking Holdings Inc : RBC raises target price to $1550 from $1535
* BorgWarner Inc : Citigroup raises price target to $30 from $23
* BorgWarner Inc : Credit Suisse raises target price to $33 from $31
* Bottomline Technologies (De) Inc : Citigroup raises price target to $46 from $43
* Bright Horizons Family Solutions Inc : Citigroup raises PT to $122 from $80
* Brightsphere Investment Group Inc : Evercore ISI raises target to $9 from $6
* Brightsphere Investment Group Inc : KBW raises target price to $9.50 from $7.25
* Brightview Holdings Inc : Credit Suisse cuts target price to $14 from $18
* Brightview Holdings Inc : Jefferies raises target price to $14 from $12
* Cabot Microelectronics Corp : Citigroup cuts price target to $140 from $175
* Cactus Inc : zephirin Group raises price objective to $12 from $8
* Calithera Biosciences Inc : Jefferies raises target price to $9 from $6
* Calyxt Inc : BMO cuts price target to $7 from $13
* Calyxt Inc : BMO cuts to market perform from outperform
* Camping World Holdings Inc : Credit Suisse raises target price to $12 from $11
* Camping World Holdings Inc : JP Morgan raises price target to $11 from $10
* Capstar Financial Holdings Inc : KBW raises target price to $11 from $10.50
* Cargurus Inc : BTIG raises target price to $26 from $23
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Castlight Health Inc : Cantor Fitzgerald cuts target price to $1 from $2
* Catasys Inc : Canaccord Genuity raises target price to $36 from $35
* CBRE Group Inc : Evercore ISI cuts target price to $48 from $50
* CBRE Group Inc : KBW cuts target price to $51 from $52
* Centerpoint Energy Inc : Guggenheim raises target price to $26 from $25
* Centerpoint Energy Inc : Keybanc raises target price to $16 from $12
* Centurylink Inc : RBC cuts target price to $10 from $14
* CF Industries Holdings Inc : Citigroup cuts price target to $29 from $31
* CF Industries Holdings Inc : Scotiabank raises target price to $32 from $31
* ChannelAdvisor Corp : Needham raises price target to $14 from $11
* Charles River Laboratories International : Credit Suisse cuts PT to $159 from $162
* Charles River Laboratories International : Evercore ISI ups PT to $176 from $154
* Charles River Laboratories International : Jefferies raises PT to $161 from $139
* Charles River Laboratories International Inc : Citigroup raises price target to $190 from $165
* Chart Industries Inc : zephirin Group raises price objective to $25 from $17
* Charter Communications Inc : Benchmark raises price target to $600 from $523
* Chemours Co : Citigroup raises price target to $13 from $8
* Cimarex Energy Co : MKM Partners raises target price to $34 from $31
* City Holding Co : Stephens cuts target price to $63 from $64.
- 05/08/2020
|
Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Q1 2020 Earnings Conference Call May 6, 2020 5:00 P.M. ET Company Participants Ami Bavishi - Director of Investor Rela
- 05/08/2020
|
Aerie Pharmaceuticals Inc (AERI) Q1 2020 Earnings Call Transcript
- AERI earnings call for the period ending March 31, 2020.
- 05/07/2020
|
Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT
- Q1 2020 Aerie Pharmaceuticals Inc Earnings Call
- 05/07/2020
|
Mizuho Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $29
|
SunTrust Robinson Humphrey Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $22
|
U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies
- Wall Street securities analysts on Thursday revised their ratings and
price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and
Solaredge Technologies.
HIGHLIGHTS
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Natera Inc : JP Morgan raises to overweight from neutral
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Solaredge Technologies : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* A. O. Smith Corp : Stephens raises target price to $40 from $37
* Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37
* Acadia Healthcare Company Inc : Deutsche Bank cuts target price to $28 from $32
* Activision Blizzard Inc : Keybanc raises target price to $80 from $68
* Adient Plc : Deutsche Bank raises target price to $20 from $15
* ADMA Biologics Inc : Oppenheimer cuts target price to $7 from $14
* Advanced Energy Industries Inc : Citigroup raises price target to $63 from $40
* Advanced Energy Industries Inc : Cowen and Company raises PT to $58 from $51
* Advanced Energy Industries Inc : D.A. Davidson raises target to $60 from $50
* Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90
* Aerie Pharmaceuticals Inc : H.C. Wainwright cuts target price to $31 from $37
* Aerie Pharmaceuticals Inc : Mizuho cuts target price to $29 from $34
* Aerie Pharmaceuticals Inc : Piper Sandler cuts target price to $35 from $45
* Aerie Pharmaceuticals Inc : SunTrust Robinson cuts price target to $22 from $26
* Agco Corp : Stephens raises target price to $65 from $60
* Air Transport Services Group Inc : Cowen and Company raises PT to $26 from $25
* Albemarle Corp : UBS cuts target price to $90 from $98
* Alexion Pharmaceuticals Inc : BMO cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Jefferies cuts price target to $111 from $112
* Alexion Pharmaceuticals Inc : Raymond James cuts target price to $156 from $159
* Alexion Pharmaceuticals Inc : SunTrust Robinson cuts target to $135 from $141
* Alexion Pharmaceuticals Inc : SVB Leerink cuts target price to $150 from $156
* Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100
* Allete Inc : Guggenheim cuts price target to $65 from $70
* Allogene Therapeutics Inc : Jefferies raises target price to $37 from $36
* Allstate Corp : Piper Sandler raises target price to $112 from $108
* Alnylam Pharmaceuticals Inc : Guggenheim raises price target to $166 from $155
* Alnylam Pharmaceuticals Inc : BMO raises target price to $171 from $145
* Alnylam Pharmaceuticals Inc : Jefferies raises price target to $165 from $142
* Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight
* Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133
* Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135
* Alnylam Pharmaceuticals Inc : Oppenheimer raises target price to $162 from $140
* Alnylam Pharmaceuticals Inc : Piper Sandler raises target to $169 from $142
* Alteryx Inc : Citigroup cuts price target to $147 from $160
* Alteryx Inc : Cowen and Company cuts target price to $135 from $145
* Alteryx Inc : Needham cuts target price to $140 from $152
* Alteryx Inc : Wedbush cuts price target to $138 from $146
* Amedisys Inc : Benchmark cuts to hold rating
* Ameriprise Financial Inc : Evercore ISI raises target price to $139 from $136
* Ametek Inc : Berenberg raises target price to $93 from $86
* Ametek Inc : Stephens cuts target price to $92 from $94
* Anaptysbio Inc : Credit Suisse raises target price to $16 from $14
* Apache Corp : Credit Suisse raises target price to $10 from $4
* Aptiv Plc : Deutsche Bank raises target price to $75 from $59
* Arcus Biosciences Inc : Wedbush raises target price to $40 from $26
* Ares Capital Corp : BMO cuts target price by $5 to $16
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Ares Management Corp : BMO raises target price to $40 from $30
* Ares Management Corp : Credit Suisse raises target price to $40 from $38
* Ares Management Corp : Jefferies raises target price to $42 from $39
* Ares Management Corp : KBW raises target price to $45 from $44
* ASGN Inc : Jefferies raises target price to $54 from $31
* Ashland Global Holdings Inc : Deutsche Bank raises target price to $70 from $65
* Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Ashland Global Holdings Inc. : SunTrust Robinson cuts price target to $75 from $87
* Aspen Technology Inc : Benchmark cuts target price to $130
* Aspen Technology Inc : Keybanc raises target price to $120 from $110
* Assetmark Financial Holdings Inc : BMO cuts target price to $23 from $26
* Assurant Inc : SunTrust Robinson cuts price target to $145 from $155
* Astronics Corp : Canaccord Genuity cuts target price to $10 from $14
* Astronics Corp : SunTrust Robinson cuts price target to $6 from $7
* Atkore International Group Inc : Citigroup raises price target to $26 from $24
* Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12
* Avanos Medical Inc : Berenberg raises target price to $33 from $30
* Avanos Medical Inc : Stephens raises target price to $38 from $30
* Axalta Coating Systems Ltd : Citigroup raises price target to $21 from $18
* Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29
* Axalta Coating Systems Ltd : Jefferies raises target price to $18 from $15
* Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23
* Axcelis Technologies Inc : D.A. Davidson raises price target to $25 from $20
* Axcella Health Inc : BTIG raises target price to $12 from $10
* Axogen Inc : Canaccord Genuity cuts target price to $12 from $22
* Axogen Inc : Jefferies cuts target price to $21 from $30
* Bank of N.T. Butterfield & Son Ltd : Citigroup raises target to $21 from $15
* Barrett Business Services Inc : Barrington Research raises PT to $52 from $48
* Barrick Gold Corp : Deutsche Bank raises target price to $34 from $25
* Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35
* Bio Rad Laboratories Inc : Citigroup raises price target to $525 from $480
* Bio Rad Laboratories Inc : Jefferies raises target price to $525 from $500
* Biocryst Pharmaceuticals Inc : Jefferies raises price target to $9 from $8
* Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8
* Biotelemetry Inc : Benchmark cuts target price to $52 from $55
* Black Knight Inc : KBW raises target price to $70 from $68
* Black Knight Inc : Stephens raises target price to $88 from $84
* Black Knight Inc : Wedbush raises target price to $70 from $66
* Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5
* Blackbaud Inc : Evercore ISI cuts target price to $48 from $55
* Blucora Inc : Benchmark cuts price target to $25 from $37
* BMC stock Holdings Inc : Stephens raises target price to $25 from $22
* BMC stock Holdings Inc : SunTrust Robinson raises price target to $26 from $22
* BorgWarner Inc : Jefferies raises target price to $33 from $30
* BorgWarner Inc : JP Morgan raises price target to $35 from $32
* BorgWarner Inc : Oppenheimer cuts target price to $44 from $45
* BorgWarner Inc : RBC raises target price to $31 from $29
* Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.
- 05/07/2020
|
HC Wainwright & Co. Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $31
|
Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates
- Aerie (AERI) delivered earnings and revenue surprises of -12.00% and -3.32%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2020
|
Aerie Pharmaceuticals Q1 EPS $(0.840) Misses $(0.770) Estimate, Sales $20.341M Beat $20.060M Estimate
|
Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, today reported financial results for the first quarter ended March 31, 2020 and provided a general business update, including the impact of the COVID-19 pandemic on company operations.
- 05/06/2020
|
Aerie Pharmaceuticals, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 6, 2020 at 5:00 ...
- 05/06/2020
|
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
- 05/06/2020
|
Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the Bank of America Securities 2020 Healthcare Conference on Tuesday, May 12, 2020 at 8:20 a.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.
- 05/05/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Sees Large Increase in Short Interest
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 9,720,000 shares, an increase of 5.1% from the March 31st total of 9,250,000 shares. Based on an average daily trading volume, of 962,900 shares, the short-interest ratio is presently 10.1 […]
- 05/02/2020
|
Analysts' Top Healthcare Picks: Lemaitre Vascular (LMAT), Aerie Pharma (AERI)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (LMAT), Aerie Pharma (AERI) and BioLife
- 05/01/2020
|
Analysts’ Top Healthcare Picks: Lemaitre Vascular (LMAT), Aerie Pharma (AERI)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lemaitre Vascular (
LMAT
–
Research Report
), Aerie Pharma (
AERI
–
Research Report
) and BioLife Solutions (
BLFS
–
Research Report
) with bullish sentime
- 05/01/2020
|
Global Ophthalmology Therapeutics Market (2020 to 2024) - Featuring AbbVie, Aerie Pharmaceuticals & Bayer Among Others
- Dublin, May 01, 2020 -- The "Global Ophthalmology Therapeutics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The author has.
- 05/01/2020
|
Needham Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $38
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Shares Sold by Cwm LLC
- Cwm LLC trimmed its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 4.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 260,941 shares of the company’s stock after selling 11,556 shares during the period. Cwm LLC owned 0.56% of Aerie Pharmaceuticals worth […]
- 04/30/2020
|
Needham Thinks Aerie Pharma's Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $38.00. The company's shares closed last
- 04/30/2020
|
Needham Thinks Aerie Pharma’s Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price
- 04/30/2020
|
Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced today that its first quarter 2020 financial results will be released after the market closes on Wednesday, May 6, 2020. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.
- 04/29/2020
|
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?
- Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?
- Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/28/2020
|
Insights on the Worldwide Ophthalmology Therapeutics Industry to 2024 - Key Drivers and Challenges - ResearchAndMarkets.com
- The "Global Ophthalmology Therapeutics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
- 04/28/2020
|
Crispr Therapeutics (NASDAQ:CRSP) vs. Aerie Pharmaceuticals (NASDAQ:AERI) Head-To-Head Contrast
- Crispr Therapeutics (NASDAQ:CRSP) and Aerie Pharmaceuticals (NASDAQ:AERI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation. Profitability This table compares Crispr Therapeutics and Aerie Pharmaceuticals’ net margins, return on equity and return […]
- 04/28/2020
|
Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy?
|
Mizuho Securities Thinks Aerie Pharma's Stock is Going to Recover
- Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $34.00. The company's shares closed
- 04/24/2020
|
Mizuho Securities Thinks Aerie Pharma’s Stock is Going to Recover
- Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a
- 04/24/2020
|
Needham Thinks Aerie Pharma's Stock is Going to Recover
- Needham analyst Serge Belanger assigned a Buy rating to Aerie Pharma (AERI) today and set a price target of $40.00. The company's shares closed last
- 04/24/2020
|
Needham Thinks Aerie Pharma’s Stock is Going to Recover
- Needham analyst
Serge Belanger
assigned a
Buy
rating to Aerie Pharma (
AERI
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Thursday at $14.01, close to its 52-week low of $10.81.
According to
TipRanks.co
- 04/24/2020
|
Frontier Capital Management Co. LLC Decreases Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Frontier Capital Management Co. LLC lowered its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 22.7% in the 1st quarter, HoldingsChannel reports. The firm owned 420,539 shares of the company’s stock after selling 123,676 shares during the quarter. Frontier Capital Management Co. LLC’s holdings in Aerie Pharmaceuticals were worth $5,677,000 as of its most […]
- 04/20/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Sees Large Decrease in Short Interest
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the target of a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 9,250,000 shares, a drop of 20.1% from the March 15th total of 11,576,000 shares. Based on an average daily trading volume, of 1,000,000 shares, the short-interest ratio […]
- 04/20/2020
|
Q1 2020 EPS Estimates for Aerie Pharmaceuticals Inc (NASDAQ:AERI) Boosted by Oppenheimer
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) – Analysts at Oppenheimer lifted their Q1 2020 EPS estimates for shares of Aerie Pharmaceuticals in a report issued on Monday, April 13th. Oppenheimer analyst E. Rajavelu now anticipates that the company will post earnings of ($0.56) per share for the quarter, up from their previous forecast of ($0.59). Oppenheimer currently […]
- 04/18/2020
|
Mizuho Securities Thinks Aerie Pharma's Stock is Going to Recover
- In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of $34.00. The company's
- 04/17/2020
|
Mizuho Securities Thinks Aerie Pharma’s Stock is Going to Recover
- In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI – Research
- 04/17/2020
|
This is what access to clean water looks like for a First Nation in a remote corner of Ontario
- With a lack of infrastructure, funding, treatment plants and even roads, the struggle for drinking water seems never-ending.
- 04/17/2020
|
Goldman Sachs Group Inc. Has $2.21 Million Stock Holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Goldman Sachs Group Inc. cut its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 79.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 91,596 shares of the company’s stock after selling 357,539 shares during the period. Goldman Sachs Group Inc. owned about 0.20% of Aerie […]
- 04/14/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Given New $34.00 Price Target at Mizuho
- Aerie Pharmaceuticals (NASDAQ:AERI) had its price objective reduced by Mizuho from $54.00 to $34.00 in a research report sent to investors on Monday, The Fly reports. They currently have a buy rating on the stock. Several other analysts have also recently weighed in on AERI. BidaskClub upgraded shares of Aerie Pharmaceuticals from a strong sell […]
- 04/14/2020
|
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
- Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
- 04/13/2020
|
Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak
- Aerie (AERI) suspends annual guidance as volumes get impacted due to the COVID-19 outbreak.
- 04/13/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) PT Lowered to $26.00 at Oppenheimer
- Aerie Pharmaceuticals (NASDAQ:AERI) had its price objective dropped by analysts at Oppenheimer from $28.00 to $26.00 in a research note issued on Monday, BenzingaRatingsTable reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would suggest a potential upside of 70.49% from the company’s previous close. Several other analysts have also […]
- 04/13/2020
|
Needham & Company LLC Reiterates "Buy" Rating for Aerie Pharmaceuticals (NASDAQ:AERI)
- Aerie Pharmaceuticals (NASDAQ:AERI)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued to clients and investors on Monday, AnalystRatings.com reports. They presently have a $40.00 target price on the stock. Needham & Company LLC’s price objective points to a potential upside of 162.30% from the stock’s current price. […]
- 04/13/2020
|
Oppenheimer Thinks Aerie Pharma's Stock is Going to Recover
- Oppenheimer analyst Esther Rajavelu maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $26.00. The company's shares closed
- 04/13/2020
|
Oppenheimer Thinks Aerie Pharma’s Stock is Going to Recover
- Oppenheimer analyst Esther Rajavelu maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price
- 04/13/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Expected to Announce Earnings of -$0.72 Per Share
- Brokerages expect Aerie Pharmaceuticals Inc (NASDAQ:AERI) to post earnings per share (EPS) of ($0.72) for the current quarter, Zacks reports. Six analysts have provided estimates for Aerie Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.87) and the highest is ($0.59). Aerie Pharmaceuticals reported earnings of ($0.78) per share during the same quarter last year, which […]
- 04/13/2020
|
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and Neurocrine (NBIX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Neurocrine (NBIX) with bullish
- 04/13/2020
|
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (NASDAQ: AERI) and Neurocrine (NASDAQ: NBIX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (
AERI
–
Research Report
) and Neurocrine (
NBIX
–
Research Report
) with bullish sentiments.
Aerie Pharma (AERI)
Needham analyst
Serge Belang
- 04/13/2020
|
Aerie Pharma (AERI) Receives a Buy from Mizuho Securities
- In a report released yesterday, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI), with a price target of $54.00. The
- 04/13/2020
|
Aerie Pharma (AERI) Receives a Buy from Mizuho Securities
- In a report released yesterday, Difei Yang from Mizuho Securities maintained a Buy rating on Aerie Pharma (AERI – Research
- 04/13/2020
|
CORRECTION: Mizuho Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $34; Initial Headline Had Incorrect Ticker And Company Name
|
Sunday’s Highlights at Noon: El Pollo LoCo (LOCO), Navios Maritime Partners (NMM), Halliburton (HAL), LendingClub (LC), Aerie Pharma (AERI)
- So far Sunday, April 12, NASDAQ is down -0.19% and the S&P is up 0.63%. Let’s take a look at
- 04/12/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Expected to Post Quarterly Sales of $21.03 Million
- Analysts expect that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will report $21.03 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Aerie Pharmaceuticals’ earnings, with the highest sales estimate coming in at $22.84 million and the lowest estimate coming in at $18.70 million. Aerie Pharmaceuticals reported sales of […]
- 04/12/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Upgraded to "Sell" at BidaskClub
- Aerie Pharmaceuticals (NASDAQ:AERI) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday, BidAskClub reports. A number of other research firms have also issued reports on AERI. JMP Securities reaffirmed an “average” rating and set a $35.00 target price on shares […]
- 04/11/2020
|
Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19
- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today provided a business update associated with the impact of the global Coronavirus disease (COVID-19) pandemic on Company operations.
- 04/09/2020
|
Aerie Pharmaceuticals withdraws FY20 guidance AERI
- Aerie Pharmaceuticals withdraws FY20 guidance AERI
- 04/09/2020
|
Aerie Pharmaceuticals shares are trading lower after the company provided a 2020 company and guidance update in response to the coronavirus.
|
Aerie Pharmaceuticals (NASDAQ:AERI) Shares Up 5.9%
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares shot up 5.9% during trading on Tuesday . The stock traded as high as $12.95 and last traded at $12.71, 926,536 shares changed hands during trading. A decline of 6% from the average session volume of 984,790 shares. The stock had previously closed at $12.00. Several research firms have commented […]
- 04/08/2020
|
Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced that
- 04/07/2020
|
1,143,300 Shares in Aerie Pharmaceuticals Inc (NASDAQ:AERI) Bought by Franklin Resources Inc.
- Franklin Resources Inc. acquired a new position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,143,300 shares of the company’s stock, valued at approximately $27,634,000. Franklin Resources Inc. owned 2.46% of Aerie Pharmaceuticals as of its […]
- 04/07/2020
|
Victory Capital Management Inc. Boosts Holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Victory Capital Management Inc. lifted its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 17.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,370 shares of the company’s stock after buying an additional 1,259 shares during the period. Victory Capital Management Inc.’s holdings […]
- 04/06/2020
|
Head to Head Survey: Aerie Pharmaceuticals (NASDAQ:AERI) & SpringWorks Therapeutics (NASDAQ:SWTX)
- SpringWorks Therapeutics (NASDAQ:SWTX) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership. Analyst Ratings This is a summary of current recommendations for SpringWorks Therapeutics and Aerie Pharmaceuticals, […]
- 04/06/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Stock Price Down 7%
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) was down 7% during mid-day trading on Friday . The stock traded as low as $11.92 and last traded at $12.17, approximately 1,067,629 shares changed hands during mid-day trading. An increase of 10% from the average daily volume of 973,765 shares. The stock had previously closed at $13.08. Several equities analysts […]
- 04/05/2020
|
Here’s Why Aerie Pharmaceuticals (NASDAQ:AERI) Can Manage Its Debt Despite Losing Money
- Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
- 04/04/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Shares Purchased by Alliancebernstein L.P.
- Alliancebernstein L.P. boosted its holdings in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 21.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 661,859 shares of the company’s stock after purchasing an additional 117,437 shares during the quarter. Alliancebernstein L.P. owned approximately 1.43% of Aerie Pharmaceuticals worth […]
- 04/04/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Stake Lowered by Credit Suisse AG
- Credit Suisse AG reduced its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 85.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,915 shares of the company’s stock after selling 181,126 shares during the period. Credit Suisse AG owned […]
- 04/04/2020
|
Needham Thinks Aerie Pharma's Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $40.00. The company's shares closed last
- 04/03/2020
|
Needham Thinks Aerie Pharma’s Stock is Going to Recover
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a price
- 04/03/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Mizuho
- 04/03/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this
- 04/03/2020
|
Bank of New York Mellon Corp Buys 43,633 Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Bank of New York Mellon Corp raised its stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,387,682 shares of the company’s stock after acquiring an additional 43,633 shares during the quarter. Bank […]
- 04/03/2020
|
Gone: Triangle public companies lose $30 billion in value during 1Q 2020
- Most Triangle public companies have seen their market valuations fall in 1Q2020.
- 04/02/2020
|
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature
- Success in clinical trials doesn't guarantee success on the market.
- 04/01/2020
|
First Republic Investment Management Inc. Raises Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- First Republic Investment Management Inc. grew its position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 63.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,585 shares of the company’s stock after acquiring an additional 6,859 shares during the period. First Republic […]
- 04/01/2020
|
Stifel Maintains Buy on Aerie Pharmaceuticals, Lowers Price Target to $40
|
Aerie Pharmaceuticals participates in a conference call with Stifel AERI
- Aerie Pharmaceuticals participates in a conference call with Stifel AERI
- 03/31/2020
|
3,208 Shares in Aerie Pharmaceuticals Inc (NASDAQ:AERI) Purchased by Great West Life Assurance Co. Can
- Great West Life Assurance Co. Can acquired a new stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 3,208 shares of the company’s stock, valued at approximately $77,000. A number of other large investors have also recently made changes to their positions in the stock. Schroder Investment Management Group […]
- 03/30/2020
|
Belpointe Asset Management LLC Makes New $156,000 Investment in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Belpointe Asset Management LLC bought a new position in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,472 shares of the company’s stock, valued at approximately $156,000. Other institutional investors have also recently […]
- 03/30/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Short Interest Update
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totalling 11,576,000 shares, a decrease of 6.5% from the February 27th total of 12,380,000 shares. Currently, 28.8% of the shares of the stock are short sold. Based on […]
- 03/30/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Rating Reiterated by Needham & Company LLC
- Aerie Pharmaceuticals (NASDAQ:AERI)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research report issued on Friday, AnalystRatings.com reports. They presently have a $40.00 price objective on the stock. Needham & Company LLC’s price objective points to a potential upside of 206.51% from the company’s previous close. A number of other […]
- 03/29/2020
|
Reviewing Agenus (NASDAQ:AGEN) & Aerie Pharmaceuticals (NASDAQ:AERI)
- Agenus (NASDAQ:AGEN) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Earnings and Valuation This table compares Agenus and Aerie Pharmaceuticals’ revenue, earnings per share and valuation. […]
- 03/28/2020
|
Needham Sticks to Their Buy Rating for Aerie Pharma (AERI)
- Needham analyst Serge Belanger maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $40.00. The company's shares closed last
- 03/27/2020
|
Needham Sticks to Their Buy Rating for Aerie Pharma (AERI)
- Needham analyst
Serge Belanger
maintained a
Buy
rating on Aerie Pharma (
AERI
–
Research Report
) today and set a price target of
$40.00
. The company’s shares closed last Monday at $13.50, close to its 52-week low of $10.80.
According to
TipRanks.co
- 03/27/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from Mizuho
- 03/27/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After Needham and Oppenheimer gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this
- 03/27/2020
|
Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap
- And just like that, stocks have landed back in the green. Following a several week long market performance that can only be described as tumultuous, the market notched its best single-day advance in almost twelve years. Driven by Congress’s $2 trillion coronavirus spending bill designed to provide relief from the pandemic’s economic impact, the Dow Jones posted its largest one-day climb since 1933, a more than 11% jump to be precise. As for the S&P; 500, it recovered from its lowest point since 2016, with it making its biggest one-day move since October 2008.With it remaining unclear if the improved sentiment has pushed the market to an inflection point, investors are relying on the pros for guidance. One such expert is investing guru James Flynn. The combination of a bachelor’s of science degree in cellular and molecular biology and economics from the University of Michigan and years of experience as an analyst has given him a clear insight into the world of healthcare. Flynn went on to join investing firm Deerfield in 2000, and has since earned a reputation as one of the best healthcare stock pickers in the game. With vast knowledge of the space, it’s clear why Wall Street pays attention when the investing titan pulls the trigger.To this end, we pulled up TipRanks’ database to take a closer look at three Buy-rated stocks Flynn picked up during the recent market sell-off. Upon further examination, each ticker boasts a bargain price tag and substantial upside potential. Let's take a closer look.Aerie Pharmaceuticals (AERI)Specializing in eye care, Aeri Pharmaceuticals develops and commercializes innovative therapies to treat glaucoma, dry eye, retinal diseases and other diseases of the eye. While shares have slumped lower in the last month, some members of the Street believe its current $13.49 share price is an attractive entry point.Taking this stance is James Flynn. On March 24, the healthcare pro boosted his AERI holding by 43%, or 759,892 shares. With his total position coming in at 2,532,147 shares, he is now a 5.5% owner of the company.After speaking with management on the same day that Flynn made the purchase, Mizuho Securities analyst Difei Yang remains confident in AERI’s long-term growth prospects. As the COVID-19 pandemic weighs down other tickers, Yang is expecting some short-term revenue upside for AERI. With patients preparing to shelter in place and less elective procedures like laser therapy and surgical interventions are performed, more doctors and pharmacies are promoting and filling 90-day prescriptions of its Rhopressa and Rocklatan products.“We believe that this may create a short-term tailwind to revenues as patients stock up on supply...In addition, management noted that doctors are increasingly writing scripts without office visits, and that home prescription delivery is being increasingly pushed; this could offset partially the headwinds from ‘social distancing’,” Yang explained.It should be noted that there’s a risk that as healthcare providers become more overwhelmed by the pandemic and as the pace of prescription refills slows, revenues could take a hit in the next one to three months. Having said that, Yang points out that the company doesn’t expect there to be an impact on clinical trial timing and that it has enough supply to weather the current storm. “Furthermore, we believe that AERI has sufficient cash on hand and has a solid balance sheet,” the analyst added.In line with this optimistic approach, Yang reiterated a Buy rating and $54 price target. Should the target be met, shares could be in for a huge twelve-month gain of 300%. (To watch Yang’s track record, click here)In general, the rest of the Street is on the same page. A Strong Buy consensus rating breaks down into 9 Buys and 1 Hold dished out in the last three months. While less aggressive than Yang, the $38.20 average price target still leaves room for 180% upside growth. (See Aerie stock analysis on TipRanks)Axonics Modulation Technologies (AXNX)With the goal of becoming the leader in sacral neuromodulation, med tech company Axonics wants to provide solutions to patients with urinary and bowel dysfunction. Like Aerie, the last month has seen its share price take a fall, but at $20.76 apiece, this could be a compelling opportunity.Flynn jumped on this opportunity on March 24. Acquiring a new position, the investing guru bought almost 1.8 million AXNX shares. As a result, his stake in the company lands at 5.2%.After the company’s fourth quarter 2019 earnings release on March 4, several analysts think that AXNX represents a bright spot in an otherwise gloomy economic landscape. Even though adjusted loss per share missed the consensus estimate, revenue was in-line with management’s pre-announcement and beat the Street’s call. On top of this, management reiterated that it is on track to meet the revenue guidance for both Q1 2020 and full year 2020.As for the earnings miss, analyst Kaila Krum of SunTrust Robinson notes that it came as a result of its investments in sustainable long-term growth. AXNX is now in over 300 U.S. accounts, so these efforts are clearly paying off. “Shares of Axonics trade at about 7.5x 2021E revenue, though the company’s growth profile deserves a scarcity premium, in our view, and we think the stock will continue to move higher as the market expansion story plays out,” she commented.Bearing this in mind, Krum left a Buy recommendation on the stock. In addition, she bumped up the price target from $38 to $48, implying 117% upside potential. (To watch Krum’s track record, click here)Meanwhile, Needham’s Mike Matson argues that the results indicate AXNX is gaining market share with respect to its r-SNM product. “We think that the Q4 2019 results are evidence that the US r-SNM launch is going well and management indicated that momentum has continued to build in Q1 2020. We believe that the r-SNM launch in the US should continue to drive very strong revenue growth and upside to consensus through both market share gains and market expansion,” he stated. It makes sense, then, that Matson also kept a Buy rating and $48 price target on this healthcare name. (To watch Matson’s track record, click here)With 100% Street support, the consensus is unanimous: AXNX is a Strong Buy. At $48, the average price target matches the analysts’ forecasts. (See Axonics stock analysis on TipRanks)Brookdale Senior Living (BKD) Brookdale Senior Living is best known for being one of the largest owners and operators in the senior housing industry, boasting assets that include owned real estate, home health and a hospice business. While it hasn’t been immune to the broader market sell-off, one analyst thinks it looks like a steal based on its long-term growth prospects.Trading at $4.26 per share on March 9, this price tag was incentive enough for Flynn. Snapping up 17.3 million shares, the healthcare pro’s new position makes him a 9.4% owner of BKD.That being said, BKD’s growth story does include some headwinds. The COVID-19 pandemic has hit the space hard, and the industry is struggling with increased preparation and mitigation expenses as well as a decline in sales and move-in activities. As a result, management ultimately decided to withdraw its full year 2020 guidance given the high level of uncertainty. However, it should be noted that several of its peers have done the same.Some investors have expressed concern about the effects of the coronavirus-driven headwinds, but Jeffries analyst Jason Plagman believes BKD’s balance sheet will help it hold up strong. “While BKD's Net Debt/EBITDA remains elevated, we don't expect a NT liquidity issue given that BKD had over $300 million of cash & equivalents as of December 31 and $172 million of revolver capacity that was accessed in March... BKD has $339 million of debt maturities in 2020 and $331 million in 2021 which are likely to be refinanced at attractive rates,” he explained.As any negative impacts of COVID-19 will most likely speed up lease exits and restructuring, Plagman predicts upside to his full year 2021 estimate for cash flow. The analyst added, “Additionally, we believe BKD's share price doesn't adequately reflect the LT value of its assets, including its portfolio of owned communities which generate positive FCF.”All of this prompted Plagman to maintain a Buy call on this stock. However, he did cut the price target from $10 to $6, but this still implies that shares could soar 92% in the next year. (To watch Plagman’s track record, click here)What do other analysts have to say? It turns out that opinions are split evenly down the middle. 2 Buys and 2 Holds received in the previous three months add up to a Moderate Buy analyst consensus. Shares could skyrocket 132% in the next twelve months based on the $7.25 average price target. (See Brookdale's price targets on TipRanks)
- 03/25/2020
|
Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap
- And just like that, stocks have landed back in the green. Following a several week long market performance that can only be described as tumultuous, the
- 03/25/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) PT Lowered to $17.00
- Aerie Pharmaceuticals (NASDAQ:AERI) had its price target reduced by equities research analysts at Bank of America from $26.00 to $17.00 in a research report issued to clients and investors on Monday, Stock Target Advisor reports. The brokerage currently has a “neutral” rating on the stock. Bank of America‘s price objective would suggest a potential upside […]
- 03/25/2020
|
Bank of America Reiterates Hold Rating for Aerie Pharmaceuticals (NASDAQ:AERI)
- Aerie Pharmaceuticals (NASDAQ:AERI)‘s stock had its “hold” rating reiterated by equities research analysts at Bank of America in a research note issued to investors on Monday, AnalystRatings.com reports. They currently have a $17.00 price target on the stock. Bank of America‘s price target points to a potential upside of 26.02% from the company’s current price. […]
- 03/25/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Gilead Sciences (GILD) with bullish
- 03/24/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma
- 03/24/2020
|
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 23.)
Arcutis Biotherapeutics...
- 03/24/2020
|
Stocks That Hit 52-Week Lows On Monday
- On Monday morning, 720 companies hit new 52-week lows.
Noteworthy Mentions:
The largest company by market cap to set a new 52-week low was Alphabet (NASDAQ: GOOGL)...
- 03/23/2020
|
Merrill Lynch Maintains a Hold Rating on Aerie Pharma (AERI)
- In a report released today, Jason Gerberry from Merrill Lynch maintained a Hold rating on Aerie Pharma (AERI), with a price target of $17.00. The
- 03/23/2020
|
Merrill Lynch Maintains a Hold Rating on Aerie Pharma (AERI)
- In a report released today,
Jason Gerberry
from Merrill Lynch maintained a
Hold
rating on Aerie Pharma (
AERI
–
Research Report
), with a price target of
$17.00
. The company’s shares closed last Monday at $11.30, close to its 52-week low of $10.80.
- 03/23/2020
|
Financial Contrast: Aerie Pharmaceuticals (NASDAQ:AERI) and BioCryst Pharmaceuticals (NASDAQ:BCRX)
- Aerie Pharmaceuticals (NASDAQ:AERI) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of current ratings and recommmendations for Aerie Pharmaceuticals and […]
- 03/23/2020
|
B of A Securities Maintains Neutral on Aerie Pharmaceuticals, Lowers Price Target to $17
|
Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?
- Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 03/21/2020
|
Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?
- Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 03/21/2020
|
Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report?
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After H.C. Wainwright and Mizuho Securities gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from
- 03/20/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After H.C. Wainwright and Mizuho Securities gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another
- 03/20/2020
|
Mizuho Securities Sticks to Their Buy Rating for Aerie Pharma (AERI)
- Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $54.00. The company's shares closed
- 03/20/2020
|
Mizuho Securities Sticks to Their Buy Rating for Aerie Pharma (AERI)
- Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI – Research Report) today and set a
- 03/20/2020
|
$21.19 Million in Sales Expected for Aerie Pharmaceuticals Inc (NASDAQ:AERI) This Quarter
- Analysts expect that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will post $21.19 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Aerie Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $19.70 million and the highest estimate coming in at $22.84 million. Aerie Pharmaceuticals reported sales of $10.85 million […]
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After Mizuho Securities and H.C. Wainwright gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another Buy, this time from
- 03/19/2020
|
Aerie Pharma (AERI) Received its Third Buy in a Row
- After Mizuho Securities and H.C. Wainwright gave Aerie Pharma (NASDAQ: AERI) a Buy rating last month, the company received another
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
Contrasting Surface Oncology (NASDAQ:SURF) & Aerie Pharmaceuticals (NASDAQ:AERI)
- Surface Oncology (NASDAQ:SURF) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations. Profitability This table compares Surface Oncology and Aerie Pharmaceuticals’ net margins, return on equity and […]
- 03/17/2020
|
Franklin Resources Inc. Purchases New Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI)
- Franklin Resources Inc. purchased a new stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,143,300 shares of the company’s stock, valued at approximately $27,634,000. Franklin Resources Inc. owned approximately 2.47% of Aerie Pharmaceuticals as of its most […]
- 03/15/2020
|
Is Aerie Pharmaceuticals, Inc.’s (NASDAQ:AERI) CEO Being Overpaid?
- Vince Anido became the CEO of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) in 2013. First, this article will compare CEO...
- 03/14/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Sets New 1-Year Low at $13.29
- Aerie Pharmaceuticals Inc (NASDAQ:AERI)’s stock price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $13.29 and last traded at $13.68, with a volume of 19289 shares traded. The stock had previously closed at $14.55. Several research analysts recently commented on the company. ValuEngine raised Aerie Pharmaceuticals […]
- 03/14/2020
|
Needham Keeps Their Buy Rating on Aerie Pharma (AERI)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI), with a price target of $40.00. The company's
- 03/13/2020
|
Needham Keeps Their Buy Rating on Aerie Pharma (AERI)
- In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERI – Research Report),
- 03/13/2020
|
Analysts Are Bullish on Top Healthcare Stocks: Aerie Pharma (AERI), Homology Medicines (FIXX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (AERI) and Homology Medicines (FIXX) with
- 03/13/2020
|
Analysts Are Bullish on Top Healthcare Stocks: Aerie Pharma (AERI), Homology Medicines (FIXX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (
AERI
–
Research Report
) and Homology Medicines (
FIXX
–
Research Report
) with bullish sentiments.
Aerie Pharma (AERI)
Mizuho Securities an
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Holdings Increased by Charles Schwab Investment Management Inc.
- Charles Schwab Investment Management Inc. grew its stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 3.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 258,394 shares of the company’s stock after buying an additional 7,751 shares during the quarter. Charles Schwab Investment […]
- 03/12/2020
|
Piper sees trial disruption risk, calls out Moderna, Inovio as 'COVID-19 plays' MRNA;INO;OPK;GILD;REGN;BIIB;AMGN;DCPH;RIGL;MNTA;QURE;FGEN;BPMC;DBVT;BMRN;TBPH;IMMU;ZGNX;RMTI;MOR;VRTX;AERI;ACAD;GBT;XLRN;BGNE;AKBA;MIST;AIMT
- Piper sees trial disruption risk, calls out Moderna, Inovio as 'COVID-19 plays' MRNA INO OPK GILD REGN BIIB AMGN DCPH RIGL MNTA QURE FGEN BPMC DBVT BMRN TBPH IMMU ZGNX RMTI MOR VRTX AERI ACAD GBT XLRN BGNE AKBA MIST AIMT
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Enzo Biochem, Inc. (NYSE: ENZ ) Centogene NV (NASDAQ: CNTG ) Inovio Pharmaceuticals Inc (NASDAQ: INO ) Spherix Inc (NASDAQ: SPEX ) ( added to Friday's advance on clinching an option agreement for coronavirus treatment) Down In The Dumps (Biotech stocks that hit 52-week lows March 9.) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc. (NASDAQ: AKRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alexion Pharmaceuticals, Inc.
- 03/10/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
Analysts Are Bullish on These Healthcare Stocks: Aerie Pharma (AERI), Oncolytics Biotech (ONCY)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma
- 03/08/2020
|
Aerie Pharmaceuticals (NASDAQ:AERI) Hits New 52-Week Low at $15.93
- Aerie Pharmaceuticals Inc (NASDAQ:AERI) hit a new 52-week low on Friday . The company traded as low as $15.93 and last traded at $16.07, with a volume of 6588 shares. The stock had previously closed at $16.89. A number of equities research analysts recently commented on AERI shares. ValuEngine raised shares of Aerie Pharmaceuticals from […]
- 03/08/2020
|
Stocks That Hit 52-Week Lows On Friday
- Friday morning, 940 companies set new 52-week lows.
Interesting Points:
The largest company by market cap to set a new 52-week low was Bank of America (NYSE: BAC).
The...
- 03/06/2020
|
Aerie Pharma (AERI) Gets a Buy Rating from Mizuho Securities
- Mizuho Securities analyst Difei Yang maintained a Buy rating on Aerie Pharma (AERI) today and set a price target of $54.00. The company's shares closed
- 03/06/2020
|
